DOD says it will act on biotechnology commission recommendations and explore mil‑spec guidance

Defense Department witnesses told the House Armed Services Committee on Oct. 11 they are taking the National Security Commission on Emerging Biotechnology's recommendations seriously and will coordinate departmental efforts around biotechnology investments.

A committee member asked whether biotech would be part of the department's top technology priorities. A senior DOD witness said biotech is included among the department's broader priorities and that a principal director in Research and Engineering (R&E) oversees biotech investments, road‑maps work and alignment across the services.

The committee also raised a commission recommendation urging clearer guidance on how biotechnologies can meet military specifications. A member described the commission’s finding that biotech products often do not fit traditional mil‑spec pathways and asked whether the department would review the recommendation that the Under Secretary for R&E work with the secretary of defense to provide guidance on proving biotech merit against mil‑specs. A senior official said, "Absolutely. And look forward to working with you and getting back to you on that."

Why it matters: Committee members said biotech could offer new options for energetics, mineral mitigation and other national‑security applications. They also flagged procurement friction points: companies told members they struggle to make biotech fit standard defense contracting categories.

Next steps: DOD witnesses committed to review the commission report more closely, coordinate across services through the R&E principal director and follow up with the committee on specific recommendations about guidance for proving biotech suitability for DOD uses.